pritelivir + moxifloxacin

Pritelivir + moxifloxacin is a combination of two pharmaceutical agents with distinct mechanisms and indications. Pritelivir is a direct-acting antiviral drug in development for the treatment of herpes simplex virus (HSV) infections—especially acyclovir-resistant HSV—in immunocompromised patients. It acts by inhibiting the viral helicase–primase enzyme complex required for HSV DNA replication and belongs to the thiazolylamide chemical class[2][5][8]. Pritelivir does not require activation by viral enzymes and can inhibit both HSV-1 and HSV-2 strains[2][5]. It is being developed by AiCuris Anti-infective Cures AG and has received fast track and breakthrough therapy designations from the US FDA[5]. Moxifloxacin is an approved fluoroquinolone antibiotic used to treat various bacterial infections including respiratory tract infections (such as pneumonia), sinusitis, chronic bronchitis exacerbations, bacterial conjunctivitis (as eye drops), plague (including prophylaxis), tuberculosis when other options are unavailable, certain sexually transmitted diseases, endocarditis in select cases, anthrax exposure prophylaxis if alternatives are lacking, salmonella or shigella in HIV-positive patients[1][3][4][6][7]. Moxifloxacin exerts its bactericidal effect by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV—enzymes essential for DNA replication—and has broad-spectrum activity against Gram-positive and Gram-negative bacteria[4][6][7].

Other names

pritelivirmoxifloxacin